FLT3 and mantle cell lymphoma: Regarding SYKi, fostamatinib showed modest activity in monotherapy in both MCL and DLBCL in a phase 1/2 study, with ORR of 11% and 22%, respectively [148], and, more recently, TAK-659, a dual inhibitor of SYK and FMS-like tyrosine kinase 3 (FLT3), showed ORR of 28% in patients with R/R DLBCL [152].